Biotech entrepreneur, CEO of Purple Biotech (NASDAQ/TASE: $PPBT)
Israel
Joined April 2009
- Tweets42
- Following88
- Followers2.6K
- Likes30
I look back at 2021 proudly as a foundation-setting year for Purple Biotech, one with clinical development achievements, personnel and culture advancements. >>
We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: bit.ly/3guxNz4
#cancerresearch #curecancer #oncology
I want to acknowledge our shareholders, leadership, Board of Directors and employees. Throughout the past year, your support and efforts have directly contributed to the company, our position, and our future. >>
Happy to share our first cohort analysis of CM24 study, reinforcing our confidence in the potential of our CEACAM1 mAb to become a safe and effective cancer treatment. #PancreaticCancer #CancerResearch #ESMO21 #ceacam1
1/4 We are excited to provide an update about our ongoing Phase 1b/2 clinical trial of CM24 for the treatment of multiple advanced cancers #oncology #CancerResearch #PancreaticCancer bit.ly/3lgn1hS
So encouraging to witness NT219 shrinking a tumor in the first dose level cohort of its ongoing Phase 1/2 clinical study. We expect to report additional data from higher dose levels of this study in the second half of this year. #ASCO21 #CancerResearch #oncology
Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer bit.ly/34OKvCQ
Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch
Over the past few years, our business has evolved significantly towards an exciting new vision and our new name, Purple Biotech, completes the transformation to our focus on advancing first-in-class oncology therapies. Exciting 2021 lies ahead ahead of us!
Important new data presented as part of our collaboration with Prof. Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky MC. Kudus to the research team at TAU & TAMSC and to our great R&D team at Kitov!
Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer #tasmc
finance.yahoo.com/news/mecha…
Very encouraging preclinical data, strongly suggest that the inhibition of the STAT3 and IRS-AKT pathways has the potential to address the tumor resistance phenotype. We look forward to initiating of the Phase 1/2 trial soon!
Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer
Back in 2017 we acquired NT-219 as a first step in our long term strategy to transform Kitov into an innovative oncology company. Pleased to deliver this milestone. Looking forward to initiating the study, wish we can bring new hope for cancer patients with this promising agent!
We are glad to announce U.S. FDA IND acceptance to conduct a phase 1/2 clinical trial of NT-219 for treatment of recurrent or metastatic solid tumors and head and neck cancer. tiny.cc/sfnjpz #cancer #headandneckcancer #solidtumors #clinicaltrials
Seven years of development have materialized into a great new treatment option now available for millions of patients suffering simultaneously from hypertension and osteoarthritis related pain. Very exciting moment!
Proud to announce the U.S. commercial launch of Consensi™, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold by Burke Therapeutics, the marketing partner of our distributor, Coeptis Pharmaceuticals. tiny.cc/qjbhpz
Isaac Israel retweeted
Proud to present today our expanded planned NT-219 clinical program for difficult to treat cancers, at the 2020 Multidisciplinary Head and Neck Cancers Symposium, being held in Scottsdale, Arizona #cancer #headandneckcancer #HNCS20
Isaac Israel retweeted
Our CEO, Isaac Israel, was recently featured on the Empowered Patient podcast with @KarenJagoda. Listen to the episode to learn more about @Kitov_Pharma and our #cancer treatments soon advancing into #ClinicalTrials: bit.ly/2kV5LDx
#transcript Isaac Israel Kitov Pharma on making cancer treatments more effective w/combination therapies to help overcome cancers' ability to develop resistance to treatment--2 cancer treatments soon to advance to clinical trials #oncology #immunoOncology empoweredpatientradio.com/de…
Isaac Israel retweeted
We signed an amended marketing & distribution agreement with Coeptis for commercialization of Consensi, our FDA-approved #hypertension & #osteoarthritis pain drug, in the U.S. Commercial batches will soon be ready for packaging & shipping. Read more: bit.ly/2peCQMw
Isaac Israel retweeted
Our VP of Research and Development, Dr. Hadas Reuveni, recently spoke to @medicalresearchnews about the background, main findings, key takeaways and more from our current study on NT-219. Read the full interview here: bit.ly/2opzyWG
Welcome Dr. Rowinsky. It is a pleasure and an honor to have you on board. Kitov’s team and myself are looking forward to working closely with you in the long journey to bring new hopes to many hard-to-treat cancer patients.
We're excited to announce the appointment of oncology veteran, Dr. Eric Rowinsky, as Chairman of #Kitov's board of directors. He brings over two decades of corporate strategy, #OncologyResearch and #DrugDevelopment expertise. Click here to learn more: bit.ly/2n1adBZ
